CB2 Insights (CSE:CBII; OTCQB:CBIIF) (“CB2” or the “Company”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), today reported its results for the first quarter of 2019. Additional information concerning the Company, including its unaudited financial statements and related management’s discussion and analysis (“MD&A”) for the […]
The post CB2 Insights Posts Strong Growth in Clinical Revenue and Drives Operating Efficiencies in Q1 2019 appeared first on Technical420.
You may also like
-
Looking For Top Marijuana ETFs For Q2 2021 Right Now? 2 Leading ETFs To Watch
-
Marijuana Stocks To Watch This Month With Hidden Value
-
Are These Marijuana Penny Stocks A Buy Right Now?
-
Aphria Inc. (APHA) Reminds Shareholders to Vote to Approve Proposed Aphria-Tilray Business Combination
-
The Time Is Now For Shareholders To Vote On The Tilray and Aphria MegaMerger